89bio, Inc. is a high-risk pharmaceutical company in the United States that specializes in developing therapies for liver and cardio-metabolic diseases. Their main product candidate, pegozafermin, is a glycoPEGylated analog of fibroblast growth factor 21 aimed at treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). With an ESG score of 32.9, 89bio, Inc. is dedicated to sustainability and governance practices in the pharmaceutical industry.